GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » Days Inventory

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Days Inventory : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Fusion Pharmaceuticals's Average Total Inventories for the three months ended in Mar. 2024 was $0.00 Mil. Fusion Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Fusion Pharmaceuticals's Days Inventory or its related term are showing as below:

FUSN's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 192.335
* Ranked among companies with meaningful Days Inventory only.

Fusion Pharmaceuticals's Days Inventory stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Fusion Pharmaceuticals Days Inventory Historical Data

The historical data trend for Fusion Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Pharmaceuticals Days Inventory Chart

Fusion Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Inventory
Get a 7-Day Free Trial - - - - -

Fusion Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Fusion Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Fusion Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fusion Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's Days Inventory falls into.



Fusion Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Fusion Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

Days Inventory (A: Dec. 2023 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (0 + 0) / 1 ) / 0*365
=0 / 0*365
=N/A

Fusion Pharmaceuticals's Days Inventory for the quarter that ended in Mar. 2024 is calculated as:

Days Inventory (Q: Mar. 2024 )
=Average Total Inventories / Cost of Goods Sold*Days in Period
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=( (0 + 0) / 1 ) / 0*365 / 4
=0 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fusion Pharmaceuticals  (NAS:FUSN) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Fusion Pharmaceuticals's Inventory Turnover for the three months ended in Mar. 2024 is calculated as

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Fusion Pharmaceuticals's Inventory to Revenue for the three months ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.


Fusion Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Executives
Teresa Marie Bitetti director 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender director 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev officer: Chief Medical Officer C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant director, officer: Chief Executive Officer FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon officer: Chief Scientific Officer C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat officer: President and CBO FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom director 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee director C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley officer: Chief Financial Officer 251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p. 10 percent owner 18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary officer: Chief Medical Officer 830 WINTER STREET, WALTHAM MA 02452

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Headlines